Sunstone Capital
Sunstone Life Science Ventures, established in 2007 and based in Copenhagen, Denmark, is a venture capital firm that focuses on early-stage investments in the life sciences sector. The firm primarily targets companies involved in specialty pharmaceuticals, biotechnology, oncology, and diagnostic equipment. Sunstone manages multiple funds that have invested across Norway, Sweden, and the United Kingdom, aiming to support innovative ventures that develop novel pharmaceutical ingredients for therapeutic applications. By concentrating on the life sciences domain, Sunstone seeks to foster advancements that can significantly impact human health and medical treatments.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Corti is an artificial intelligence platform designed to assist emergency medical dispatchers in making critical, life-saving decisions. By enhancing the medical triaging process, Corti reduces errors and improves the accuracy of human decision-making, ultimately aiming to save more lives in emergency situations. The company's technology serves as an intelligent partner, providing valuable insights and support to dispatchers as they navigate high-pressure scenarios.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Nuevolution AB is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. It specializes in developing drug treatments for oncology and chronic inflammatory diseases, leveraging its unique Chemetics platform for drug discovery. This platform combines proven wet chemistry and molecular biology, allowing for the synthesis and screening of over one billion small molecule compounds and synthetic biologics. Nuevolution is focused on several therapeutic programs, including ROR?t inhibitors and IL-17A inhibitors for chronic inflammatory diseases, as well as GRP78 for oncology. The company has established collaborations with notable pharmaceutical partners, including Amgen and Janssen Biotech, and is involved in joint ventures aimed at discovering novel small molecule drugs targeting epigenetic factors. Through its innovative technology, Nuevolution aims to address significant unmet medical needs in various therapeutic areas.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
Biomonitor, founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen, specializes in pharmaceutical development services. The company leverages Professor Bendtzen's extensive research experience in inflammation and immunology, particularly his discoveries related to patient responses to biopharmaceuticals. It has been established that some patients develop antibodies against the proteins and peptides used in these treatments, which can hinder their efficacy. Consequently, Biomonitor focuses on creating methods to monitor these biopharmaceuticals, ensuring that patients receive optimal therapeutic benefits. Since its inception, the company has experienced significant growth, reflecting its commitment to improving patient care in chronic disease management.